Ovarian Cancer Drug Study = Improvments in Survival

http://youtu.be/gkrMqMH0yRo Dr. Maurie Markman, vice president for clinical research talks about a study done in Japan with Paclitaxel and Carboplatin a standard drug regimen for the treatment of Ovarian Cancer. The study results, published in The Lancet in September 2009 indicates that weekly Paclitaxel plus Carboplatin improved survival of women with epithelial ovarian cancer and may represent a new treatment option.